MedTrace Logo

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

NCT05808634 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2025-09-25

No results posted yet for this study

Summary

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

Conditions

  • Advanced Adenocarcinoma

Interventions

DRUG

BA3182

Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM

Sponsors & Collaborators

  • BioAtla, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-14
Primary Completion
2028-09-15
Completion
2028-09-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05808634 on ClinicalTrials.gov